Insight Molecular Diagnostics Inc. IMDX
2.77 USD -0.09 (-3.32%)
Nov 3, 2026, 3:40 PM EST
2.74 Day range 3.12
2.42 52-week range 8.51
- YTD
- -63.13%
- 1 year
- -54.82%
- Market cap
- 90.48M
- EPS (ttm)
- -1.52
- YTD return
- -63.13%
- 1-year return
- -54.82%
- Volume
- 76.78K
- Avg volume
- 245.65K
- Open
- 3.12
- Previous close
- 2.86
- Day's range
- 2.74 – 3.12
- 52-week range
- 2.42 – 8.51
2Y -0.10 (-3.45%)
Financials — quick view
IMDX Revenue — quarterly 239.00K
IMDX Net income — quarterly -11.26M
IMDX EPS — quarterly -0.31
News
Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis 
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch 
iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale 
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference 
LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8 
Transcript: Insight Molecular Q2 2026 Earnings Conference Call 
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript - Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing 
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on IMDX — it syncs with the Stock Master app.